Clinical Trials Browser

Active not recruiting × OTHER × Anastrozole × Clear all

NCT01953588 2026-06-05

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Phase 3 Active not recruiting

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT02918084 2026-05-06

GIM10-CONSENT

Phase 3 Active not recruiting

Breast Neoplasms

NCT02942355 2026-05-05

Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Phase 2 Active not recruiting

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT04569747 2026-04-02

ADEPT

Phase 2 Active not recruiting

Breast Neoplasms

NCT02947685 2026-02-12

PATINA

Phase 3 Active not recruiting

518 enrolled 15 charts

Breast Neoplasms

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT04584853 2026-01-14

POETIC-A

Phase 3 Active not recruiting

Breast Cancer Female

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT05150652 2026-01-07

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT01723774 2025-12-09

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Phase 2 Active not recruiting

84 enrolled 17 charts

Breast Neoplasms

NCT04272801 2025-10-22

POWER

Phase 2 Active not recruiting

84 enrolled 9 charts

Breast Neoplasms

NCT04158362 2025-09-22

AMBRE

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT04134598 2025-08-29

EUROPA

Phase 3 Active not recruiting

Breast Neoplasms

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Phase 1/2 Active not recruiting

Breast Diseases, Breast Neoplasms

NCT03944434 2025-02-26

FACILE

Phase 2 Active not recruiting

Breast Neoplasms

NCT04719273 2025-01-08

Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

Phase 3 Active not recruiting

Breast Neoplasms

NCT02603679 2021-08-03

PREDIX LumB

Phase 2 Active not recruiting

Breast Neoplasms

NCT02592083 2020-07-07

PREDIX LumA

Phase 2 Active not recruiting

Breast Neoplasms

NCT02338310 2020-02-17

POETIC

Phase 3 Active not recruiting

Breast Neoplasms